A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of HOT-3010 to Adalimumab Among Healthy Chinese Male Subjects

Original Research Article：

Frontiers in Pharmacology

https:// 10.3389/fphar.2021.646171